Deep Track Capital: Platform Profile

Overview

Deep Track Capital is a Greenwich, Connecticut investment manager focused exclusively on life sciences. Its first-party materials describe long-term partnerships with leading public and pre-IPO biotechnology companies and an approach that can lead transactions, build syndicates or participate alongside other investors.

That makes Deep Track a public/private biotech crossover manager rather than a public-equity-only hedge fund.

May fit better for

• investors seeking specialist biotechnology exposure;
• allocators comfortable with public and pre-IPO crossover investing;
• investors able to evaluate clinical and regulatory risk;
• qualified investors seeking concentrated life-sciences expertise;
• investors comfortable with private-company liquidity and valuation risk.

May fit less well for

• investors seeking broad sector diversification;
• retail users seeking public self-service fund access;
• users who treat a biotech 13F as the complete portfolio;
• investors uncomfortable with binary trial or regulatory outcomes;
• investors expecting one universal minimum or fee schedule.

Deep Track is SEC registered

• Legal adviser: Deep Track Capital, LP
• CRD: 312459
• SEC number: 801-120500
• SEC registration effective: 2021-03-12
• SEC registered investment adviser: Yes

Current regulatory AUM is $8.373B

Current March 31, 2026 Form-ADV-derived data:

• Regulatory AUM: $8.373B
• Regulatory AUM exact: $8,373,382,671
• Regulatory AUM as of: 2026-03-31
• Discretionary AUM: $8.373B
• Client accounts: 5
• Employees: 19

Q2 2026 13F value is $6.870B

Regulatory filings show:

• Q2 2026 13F value: $6.870B
• Q2 2026 13F as of: 2026-06-30
• Q2 2026 13F position count: 67
• Q2 2026 13F filing ID: 000185608326000004

Some filing processors count rows/positions differently.

The package uses 67 as the preferred position-count reference but does not treat parser-count differences as a substantive holdings conflict.

First-party strategy is life-sciences crossover investing

Current first-party team and firm materials support:

• Life sciences only: Yes
• Biotechnology focus: Yes
• Public company investing: Yes
• Pre IPO investing: Yes
• Long term partnerships: Yes
• Transaction lead capability: Yes
• Syndicate building capability: Yes

The public/pre-IPO mix is central.

Founder and CIO

• Founder CIO: David Kroin
• Healthcare investing experience: 25+ years

Kroin previously co-founded Great Point Partners before launching Deep Track.

The experience reference is descriptive, not a guarantee of results.

Current private-fund platform

Current Form-ADV-derived data:

• Private fund count: 2
• Private fund gross assets: $8.4B
• Private fund type: Hedge Fund

The values are close because the client base is concentrated in pooled vehicles, but GAV and RAUM remain distinct definitions.

13F omits private/pre-IPO exposure

A Q1 filing included an XBI put position, illustrating that some options can appear while the filing remains incomplete.

Universal terms remain undisclosed

• Public self service retail signup: No

Assessment

Deep Track's $6.870B Q2 13F is substantial, but the firm's identity explicitly includes pre-IPO biotechnology investing.

The gap between the filing and $8.373B RAUM is therefore analytically meaningful: public long securities are only part of the crossover platform.